Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JY 231

Next Previous
Drug Profile

JY 231

Alternative Names: JY-231

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Shenzhen Genocury Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown B-cell leukaemia; B-cell lymphoma

Most Recent Events

  • 30 Apr 2025 Adverse events and efficacy data from a clinical trial in B-cell leukaemia and B-cell lymphoma (Second-line therapy or greater) released by Shenzhen Genocury Biotech
  • 23 Apr 2025 Affiliated Hospital of Guangdong Medical University plans a Clinical trial for Non Hodgkin's lymphoma and Precursor cell lymphoblastic leukaemia lymphoma (In children, In adolescents, In adults, In the elderly, Second-line therapy or greater) (IV) in April 2025 (NCT06940960)
  • 31 Mar 2025 Zhejiang University plans a clinical trial for Precursor-B-cell-lymphoblastic-leukaemia-lymphoma (Second-line therapy or greater) in China (IV, Injection) in March 2025 (NCT06902025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top